CSF complement proteins are elevated in prodromal to moderate Alzheimer's disease patients and are not altered by the anti‐tau antibody semorinemab
Cerebrospinal fluid (CSF) complement proteins C4a, C3a, Bb, C4, C3, and factor B levels were increased in Alzheimer's disease (AD) patients compared to a separate cognitively unimpaired (CU) cohort. Baseline CSF complement protein levels were correlated with neuro-axonal degeneration and glial activation biomarkers in AD patients. The investigational anti-tau antibody semorinemab did not impact CSF complement protein levels or activity relative to the placebo arm.
Authors
- Jesse E. Hanson (ORCID: https://orcid.org/0000-0003-3059-5132)
- Edmond Teng (ORCID: https://orcid.org/0000-0002-1375-857X)
- Rajini Nagaraj
- Julie Lee (ORCID: https://orcid.org/0000-0002-1395-5397)
- Anne Biever (ORCID: https://orcid.org/0000-0002-0941-4301)
- Felix L. Yeh (ORCID: https://orcid.org/0000-0003-4069-3035)
- Cecília Monteiro (ORCID: https://orcid.org/0000-0001-8109-5395)
- Gwendlyn Kollmorgen
- Cosme Sandoval
- Sandra Sanabria Bohórquez (ORCID: https://orcid.org/0000-0003-2890-2076)
- Balázs István Tóth (ORCID: https://orcid.org/0000-0002-4103-4333)
- Stephen Schauer (ORCID: https://orcid.org/0000-0001-6622-8719)
- Emilia Calderon
- Jennifer Hoffman
- Johnny Gutierrez
Institutions
- Roche Pharma AG (Germany) (DE)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2024-10-06
- DOI
- https://doi.org/10.1002/alz.14271
- Citations
- 11
- Primary Topic
- Neuroinflammation and Neurodegeneration Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 2.72
Funders
- Genentech